@article{42b0a573105442f3893a99bbeda8c90c,
title = "Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary",
author = "Emily Reeve and Barbara Farrell and Wade Thompson and Nathan Herrmann and Ingrid Sketris and Magin, {Parker J.} and Lynn Chenoweth and Mary Gorman and Lyntara Quirke and Graeme Bethune and Hilmer, {Sarah N.}",
note = "Funding Information: Funding: The guideline development, publication, dissemination and implementation were funded through an NHMRC ? ARC Dementia Research Development Fellowship awarded to Emily Reeve ?APP1105777 ? 㬀 The funding body had no involvement in guideline development and 㘀 as such 㘀 the views and ?or interests of the funding body have not influenced the final recommendations ? Funding Information: Competing interests: Emily Reeve has received support to attend conferences to present work related to deprescribing by the NHMRC Cognitive Decline Partnership Centre 㘀 Canadian Frailty Network 㘀 TUTPOHRC? Program ?Western University ?? University of Sydney Medical School 㘀 Ramsay Research and Teaching Fund ??olling Institute Travel Award 㘀 Royal North Shore Hospital Scientific Staff Council ?㘀 Swiss Society of Internal Medicine and the Pharmacy Association of Nova Scotia 䀀 has received prize money from Bupa Health Foundation 䀀 and has received grants from the Canadian Frailty Network 㘀 CACB? HI ? nowledge Mobilisation Partnership Program and the US National Institutes of Health for work related to deprescribing 㬀 Barbara Farrell has received consultancy fees and grants ?including reimbursement for travel for research meetings or education sessions 匀 from the Institute for Healthcare Improvement ? College of Psychiatric and Neurologic Pharmacists 㘀 European Association of Hospital Pharmacists 㘀 Nova Scotia College of Pharmacists 㘀 Canadian Society of Hospital Pharmacists 㘀 and Ontario Pharmacists Association 䀀 and has received research grants from the Canadian Foundation for Pharmacy 㘀 Centre for Aging Brain Health and Innovation 㘀 Canadian Institute of Health Research 㘀 and Ontario Ministry of Health and Long ?Term Care for work related to deprescribing 㬀 Wade Thompson received a Master of Science stipend from government of Ontario for work on deprescribing 㘀 and speaking fees to present at conferences on deprescribing from the Advanced Learning in Palliative Medicine Conference 㘀 Ontario LonTge ?rm Care Clinicians Conference 㘀 and ?eriatrics in Primary Care conference 刀University of Ottawa ?㬀 Nathan Herrmann has received consultancy fees for dementia drug development from Lilly 㘀 Astellas and Merck ? grants from Lundbeck and Roche for dementia investigational drug trials 䀀 and support from the Canadian Consortium on Neurodegeneration in Aging 刀CCNA 匀 funded by the Canadian Institute of Health Research and several partners 㬀 Ingrid Sketris receives a partial salary stipend from Canadian Institute of Health Research 刀CIHR 匀 as part of the Canadian Network for Observational Effect Studies and has received grants from CIHR ?including funds utilized to present research results 匀 and the Nova Scotia Department of Health and Wellness 㬀 Parker Magin has received grants from the Judith Jane Mason ? Harold Stannett Williams Memorial Foundation Medical Program Grants, and the Royal Australian College of ?eneral Practitioners 㔀 Education Research ?rant for potentially related work 㬀 Sarah Hilmer has received funding from the NHMRC Cognitive Decline Partnership Centre to support work related to deprescribing in people with dementia ? ■ Publisher Copyright: {\textcopyright} 2019 AMPCo Pty Ltd",
year = "2019",
month = mar,
doi = "10.5694/mja2.50015",
language = "English",
volume = "210",
pages = "174--179",
journal = "Medical Journal of Australia",
issn = "0025-729X",
publisher = "Australasian Medical Publishing Co. Ltd",
number = "4",
}